ADC Therapeutics' Zynlonta Trial Shows 3‑Fold Higher Deaths, Shares Drop 52%

Why It Matters

The LOTIS‑5 safety signal threatens to stall the transition of Zynlonta from a third‑line to a second‑line therapy, a move that would dramatically expand its market size. A setback could also dampen investor enthusiasm for the ADC modality, which has attracted billions in capital due to its promise of delivering cytotoxic drugs directly to cancer cells while sparing healthy tissue. Moreover, the episode underscores the regulatory scrutiny surrounding mortality endpoints in oncology trials, especially for therapies that combine multiple biologics. For the broader biotech sector, ADC Therapeutics’ experience serves as a cautionary tale about the balance between efficacy and tolerability. Companies developing next‑generation ADCs may need to re‑evaluate dosing schedules, patient‑selection criteria, and combination strategies to mitigate infection‑related deaths, especially in elderly cohorts that dominate lymphoma populations.

Key Takeaways

• LOTIS‑5 trial: 27 deaths (13.2%) in Zynlonta arm vs. 9 deaths (4.6%) in control
• Shares fell 52% after results were disclosed
• Zynlonta generated $74 M in 2025 sales and $20 M in Q1 2026
• ADC Therapeutics holds $231 M in cash, runway to 2028
• Company to meet FDA in August; supplemental filing planned for Q4 2026

Pulse Analysis

ADC Therapeutics’ predicament illustrates the fragile equilibrium that ADC developers must maintain between potency and safety. The platform’s allure—delivering a highly cytotoxic payload directly to malignant B‑cells—has driven a wave of investment, yet the LOTIS‑5 data reveal that even modest increases in infection‑related mortality can outweigh efficacy gains in the eyes of regulators and investors. Historically, ADCs such as brentuximab vedotin and trastuzumab emtansine have succeeded by targeting relatively younger, less comorbid populations; Zynlonta’s pivot to an older, heavily pre‑treated DLBCL cohort amplifies vulnerability to opportunistic infections.

From a market perspective, the 52% share collapse is a stark reminder that a single trial can reset valuation expectations for niche biotech firms. The $231 million cash buffer provides a runway, but the company now faces a strategic crossroads: allocate resources to bolster the LOTIS‑7 combination, which shows a more favorable safety profile, or double down on the second‑line indication with a revised protocol. The outcome of the August FDA meeting will likely set a precedent for how aggressively the agency will demand safety mitigations for ADCs targeting frail patient groups.

Looking ahead, investors will monitor not only the FDA’s feedback but also competitor activity. Roche’s own ADC pipeline and emerging bispecific formats could siphon market share if Zynlonta’s label expansion stalls. For the ADC field at large, the episode may accelerate a shift toward next‑generation linkers and payloads designed to reduce off‑target toxicity, reinforcing the industry’s focus on precision engineering over sheer cytotoxic power.